B
Bull
Bull · 25%BWAY
$14.03
Scenario price
$14.270
-0.245 (-1.72%)At close
Loading chart…
- High
- 14.585
- Open
- 14.520
- VWAP
- 14.34
- Vol
- 67.13K
- Mkt Cap
- 100.32M
- Low
- 14.180
- Amount
- 962.92K
- EV/EBITDA, TTM
- 38.70
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
AI analysis of Brainsway Ltd (BWAY)
buyBrainsway Ltd appears to be a good buy right now due to its recent FDA approval for Deep TMS technology, which is expected to significantly boost revenues. The company reported a 35% increase in revenue to $15.5 million in the latest quarter, alongside a doubling of net income to $2.3 million. Additionally, the forward P/E ratio of 34.13 suggests growth potential at a reasonable valuation compared to historical performance. However, the RSI of 35.74 indicates that the stock is currently oversold, which may present a buying opportunity.
Valuation Metrics
The current forward P/E ratio for Brainsway Ltd (BWAY) is 34.25, compared to its 5-year average forward P/E of 42.39.
Alphio AI Price Scenarios for BWAY
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding BWAY
Events Timeline
News
9.008-27NewsfilterBrainsWay Publishes New Data on Depression Treatment
- 9.508-12Newsfilter
BrainsWay Reports 35% Revenue Growth in Q2 2026
3.508-07GlobenewswireBrainsWay Publishes Study on Depression Treatment Efficacy
9.507-29GlobenewswireBrainsWay to Report Q2 2026 Financial Results and Operational Highlights
8.507-24NASDAQ.COMBrainsway's Deep TMS Technology Receives FDA Approval
BWAY FAQ — answered by Alphio AI
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
Brainsway Ltd appears to be a good buy right now due to its recent FDA approval for Deep TMS technology, which is expected to significantly boost revenues. The company reported a 35% increase in revenue to $15.5 million in the latest quarter, alongside a doubling of net income to $2.3 million. Additionally, the forward P/E ratio of 34.13 suggests growth potential at a reasonable valuation compared to historical performance. However, the RSI of 35.74 indicates that the stock is currently oversold, which may present a buying opportunity.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.